Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Sexually Transmitted Diseases

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 107 articles:
HTML format



Single Articles


    September 2022
  1. ADEBAMOWO SN, Befano B, Cheung LC, Rodriguez AC, et al
    Different human papillomavirus types share early natural history transitions in immunocompetent women.
    Int J Cancer. 2022;151:920-929.
    PubMed     Abstract available


    July 2022
  2. GARGANO JW, McClung N, Lewis RM, Park IU, et al
    HPV type-specific trends in cervical precancers in the United States, 2008-2016.
    Int J Cancer. 2022 Jul 29. doi: 10.1002/ijc.34231.
    PubMed     Abstract available


  3. JOSHI S, Muwonge R, Kulkarni V, Mandolkar M, et al
    Can we increase the cervical cancer screening interval with an HPV test for women living with HIV? Results of a cohort study from Maharashtra, India.
    Int J Cancer. 2022 Jul 19. doi: 10.1002/ijc.34221.
    PubMed     Abstract available


  4. CLARKE MA, Deshmukh AA, Suk R, Roberts J, et al
    A Systematic Review and Meta-Analysis of Cytology and HPV-related Biomarkers for Anal Cancer Screening Among Different Risk Groups.
    Int J Cancer. 2022 Jul 6. doi: 10.1002/ijc.34199.
    PubMed     Abstract available


    June 2022
  5. AUVINEN E, Nieminen P, Pellinen J, Dillner J, et al
    HPV self-sampling with mRNA testing benefits routine screening.
    Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34170.
    PubMed     Abstract available


  6. DESAI KT, Adepiti CA, Schiffman M, Egemen D, et al
    Redesign of a rapid, low-cost HPV typing assay to support risk-based cervical screening and management.
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34151.
    PubMed     Abstract available


    May 2022
  7. GIORGI ROSSI P, Ronco G, Mancuso P, Carozzi F, et al
    Performance of HPV E6/E7 mRNA Assay as Primary Screening Test. Results from the NTCC2 Trial.
    Int J Cancer. 2022 May 17. doi: 10.1002/ijc.34120.
    PubMed     Abstract available


  8. BURGER EA, Laprise JF, Sy S, Regan MC, et al
    Now or later: Health impacts of delaying single-dose HPV vaccine implementation in a high-burden setting.
    Int J Cancer. 2022 May 5. doi: 10.1002/ijc.34054.
    PubMed     Abstract available


  9. HURTADO-SALGADO E, Cardenas-Cardenas L, Salmeron J, Luna-Gordillo R, et al
    Comparative performance of the human papillomavirus test and cytology for primary screening for high-grade cervical intraepithelial neoplasia at the population level.
    Int J Cancer. 2022;150:1422-1430.
    PubMed     Abstract available


    April 2022
  10. ADCOCK R, Nedjai B, Lorincz A, Scibior-Bentkowska D, et al
    DNA methylation testing with S5 for triage of high-risk HPV positive women.
    Int J Cancer. 2022 Apr 27. doi: 10.1002/ijc.34050.
    PubMed     Abstract available


  11. ZHANG L, Zhao X, Hu S, Chen S, et al
    Triage performance and predictive value of the human gene methylation panel among women positive on self-collected HPV test: results from a prospective cohort study.
    Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34041.
    PubMed     Abstract available


  12. GOTTSCHLICH A, Gondara L, Smith LW, Cook D, et al
    HPV-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV FOr CervicAL Cancer (HPV FOCAL) trial.
    Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34039.
    PubMed     Abstract available


  13. SAHASRABUDDHE VV, Castle PE, Schiffman M, Wentzensen N, et al
    Reply to: Comments on 'Meta-analysis of agreement/concordance statistics in studies comparing self- versus clinician-collected samples for HPV testing in cervical cancer screening'.
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34013.
    PubMed    


  14. BRENTNALL AR, Rebolj M
    Comments on: "Meta-analysis of agreement/concordance statistics in studies comparing self-versus clinician-collected samples for HPV testing in cervical cancer screening".
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34014.
    PubMed    


  15. GARSET-ZAMANI M, Carlander AF, Jakobsen KK, Friborg J, et al
    Impact of specific high-risk human papillomavirus genotypes on survival in oropharyngeal cancer.
    Int J Cancer. 2022;150:1174-1183.
    PubMed     Abstract available


    March 2022
  16. RETTIG EM, Faden DL, Sandhu S, Wong K, et al
    Detection of Circulating Tumor Human Papillomavirus DNA Before Diagnosis of HPV-Positive Head and Neck Cancer.
    Int J Cancer. 2022 Mar 9. doi: 10.1002/ijc.33996.
    PubMed     Abstract available


    February 2022
  17. ANTONSSON A, de Souza MMA, Panizza BJ, Whiteman DC, et al
    Sexual debut and association with oral HPV infection, persistence and oropharyngeal cancer - an analysis of two Australian cohorts.
    Int J Cancer. 2022 Feb 28. doi: 10.1002/ijc.33986.
    PubMed     Abstract available


  18. ARBYN M, Castle PE, Schiffman M, Wentzensen N, et al
    Meta-analysis of agreement/concordance statistics in studies comparing self- versus clinician-collected samples for HPV testing in cervical cancer screening.
    Int J Cancer. 2022 Feb 18. doi: 10.1002/ijc.33967.
    PubMed     Abstract available


    December 2021
  19. HORTLUND M, Muhr LSA, Lagheden C, Hjerpe A, et al
    Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening program.
    Int J Cancer. 2021;149:2083-2090.
    PubMed     Abstract available


  20. REBOLJ M, Mathews CS, Pesola F, Castanon A, et al
    Acceleration of Cervical Cancer Diagnosis with Human Papillomavirus Testing Below Age 30: Observational Study.
    Int J Cancer. 2021 Dec 12. doi: 10.1002/ijc.33900.
    PubMed     Abstract available


    November 2021
  21. LASSEN P, Huang SH, Su J, Waldron J, et al
    Treatment outcomes and survival following definitive (chemo) radiotherapy in HPV-positive oropharynx cancer: Large-scale comparison of DAHANCA vs PMH cohorts.
    Int J Cancer. 2021 Nov 18. doi: 10.1002/ijc.33876.
    PubMed     Abstract available


  22. SPENCER JC, Campos NG, Burger EA, Sy S, et al
    Potential Effectiveness of a Therapeutic HPV Intervention Campaign in Uganda.
    Int J Cancer. 2021 Nov 6. doi: 10.1002/ijc.33867.
    PubMed     Abstract available


    October 2021
  23. GUSTINUCCI D, Benevolo M, Cesarini E, Mancuso P, et al
    Accuracy of Different Triage Strategies for HPV Positivity in an Italian Screening Population.
    Int J Cancer. 2021 Oct 27. doi: 10.1002/ijc.33858.
    PubMed     Abstract available


  24. PEDERSEN K, Portnoy A, Sy S, Hansen BT, et al
    Switching clinic-based cervical cancer screening programs to HPV self-sampling: A cost-effectiveness analysis of vaccinated and unvaccinated Norwegian women.
    Int J Cancer. 2021 Oct 18. doi: 10.1002/ijc.33850.
    PubMed     Abstract available


  25. TAWK B, Wirkner U, Schwager C, Rein K, et al
    Tumor DNA-Methylome derived Epigenetic Fingerprint Identifies HPV-negative Head and Neck Patients at Risk for Locoregional Recurrence after Postoperative Radiochemotherapy.
    Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33842.
    PubMed     Abstract available


    September 2021
  26. BANILA C, Lorincz AT, Scibior-Bentkowska D, Clifford GM, et al
    Clinical performance of methylation as a biomarker for cervical carcinoma-in-situ and cancer diagnosis: a worldwide study.
    Int J Cancer. 2021 Sep 25. doi: 10.1002/ijc.33815.
    PubMed     Abstract available


  27. VERHOEF L, Bleeker MCG, Polman N, Steenbergen RDM, et al
    Performance of DNA methylation analysis of ASCL1, LHX8, ST6GALNAC5, GHSR, ZIC1 and SST for the triage of HPV-positive women: results from a Dutch primary HPV-based screening cohort.
    Int J Cancer. 2021 Sep 24. doi: 10.1002/ijc.33820.
    PubMed     Abstract available


  28. WRIGHT TC JR, Stoler MH, Ranger-Moore J, Fang Q, et al
    Clinical Validation of p16/Ki-67 Dual-Stained Cytology Triage of HPV-Positive Women - Results from the IMPACT Trial.
    Int J Cancer. 2021 Sep 18. doi: 10.1002/ijc.33812.
    PubMed     Abstract available


  29. TANAKA H, Suzuki M, Takemoto N, Fukusumi T, et al
    Performance of Oral HPV DNA, Oral HPV mRNA, and Circulating Tumor HPV DNA in the Detection of HPV-Related Oropharyngeal Cancer and Cancer of Unknown Primary.
    Int J Cancer. 2021 Sep 6. doi: 10.1002/ijc.33798.
    PubMed     Abstract available


    August 2021
  30. KEANE A, Ng CW, Simms KT, Nguyen D, et al
    The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of HPV screening with self-collection and digital registry support.
    Int J Cancer. 2021 Aug 7. doi: 10.1002/ijc.33759.
    PubMed     Abstract available


    July 2021
  31. VAN DER ZEE RP, Meijer CJLM, Cuming T, Kreuter A, et al
    Characterisation of anal intraepithelial neoplasia and anal cancer in HIV-positive men by immunohistochemical markers p16, Ki-67, HPV-E4, and DNA methylation markers.
    Int J Cancer. 2021 Jul 26. doi: 10.1002/ijc.33748.
    PubMed     Abstract available


  32. NAUTA IH, Heideman DAM, Brink A, van der Steen B, et al
    The unveiled reality of human papillomavirus as risk factor for oral cavity squamous cell carcinoma.
    Int J Cancer. 2021;149:420-430.
    PubMed     Abstract available


    June 2021
  33. VAN SCHALKWYK C, Moodley J, Welte A, Johnson LF, et al
    Modelling the impact of prevention strategies on cervical cancer incidence in South Africa.
    Int J Cancer. 2021 Jun 24. doi: 10.1002/ijc.33716.
    PubMed     Abstract available


  34. JAYARAJ R, Shaw P, Kumarasamy C, Shetty SS, et al
    Comments on "Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis".
    Int J Cancer. 2021;148:2857-2858.
    PubMed    


  35. MALAGON T, Volesky KD, Franco EL
    Reply to: Comments on cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis.
    Int J Cancer. 2021;148:2859-2860.
    PubMed    


    May 2021
  36. ARROYO MUHR LS, Hultin E, Dillner J
    Transcription of Human Papillomaviruses in Non-Melanoma Skin Cancers of the Immunosuppressed.
    Int J Cancer. 2021 May 14. doi: 10.1002/ijc.33683.
    PubMed     Abstract available


  37. TORRES-IBARRA L, Lorincz AT, Wheeler CM, Cuzick J, et al
    Adjunctive testing by cytology, p16/Ki-67 dual-stained cytology or HPV16/18 E6 oncoprotein for the management of HPV16/18 screen-positive women.
    Int J Cancer. 2021;148:2264-2273.
    PubMed     Abstract available


    April 2021
  38. GREEN LI, Mathews CS, Waller J, Kitchener H, et al
    Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testing.
    Int J Cancer. 2021;148:1850-1857.
    PubMed     Abstract available


  39. HOPPE-SEYLER K, Herrmann AL, Daschle A, Kuhn BJ, et al
    Effects of Metformin on the virus/host cell crosstalk in HPV-positive cancer cells.
    Int J Cancer. 2021 Apr 12. doi: 10.1002/ijc.33594.
    PubMed    


  40. LI N, Hu Y, Zhang X, Liu Y, et al
    DNA methylation markers as triage test for the early identification of cervical lesions in a Chinese population.
    Int J Cancer. 2021;148:1768-1777.
    PubMed     Abstract available


    March 2021
  41. VINK FJ, Dick S, Heideman DAM, De Strooper LMA, et al
    Classification of high-grade CIN by p16(ink4a) , Ki-67, HPV E4 and FAM19A4/miR124-2 methylation status demonstrates considerable heterogeneity with potential consequences for management.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33566.
    PubMed     Abstract available


    February 2021
  42. DONKEN R, van Niekerk D, Hamm J, Spinelli JJ, et al
    Declining Rates of Cervical Intraepithelial Neoplasia in British Columbia, Canada: An Ecological Analysis On The Effects of The School-Based HPV Vaccination Program.
    Int J Cancer. 2021 Feb 14. doi: 10.1002/ijc.33513.
    PubMed    


  43. TEKA B, Gizaw M, Ruddies F, Addissie A, et al
    Population-based human papillomavirus infection and genotype distribution among women in rural areas of South Central Ethiopia.
    Int J Cancer. 2021;148:723-730.
    PubMed     Abstract available


  44. HUANG HJ, Tung HJ, Yang LY, Chao A, et al
    Role of human papillomavirus status after conization for high-grade cervical intraepithelial neoplasia.
    Int J Cancer. 2021;148:665-672.
    PubMed     Abstract available


    January 2021
  45. AARNIO R, Isacson I, Sanner K, Gustavsson I, et al
    Comparison of vaginal self-sampling and cervical sampling by medical professionals for the detection of HPV and CIN2+: a randomized study.
    Int J Cancer. 2021 Jan 26. doi: 10.1002/ijc.33482.
    PubMed     Abstract available


  46. BEYRANVAND NEJAD E, Labrie C, van der Sluis TC, van Duikeren S, et al
    Interleukin-6-mediated resistance to immunotherapy is linked to impaired myeloid cell function.
    Int J Cancer. 2021;148:211-225.
    PubMed     Abstract available


    December 2020
  47. ANTONSSON A, de Souza M, Wood ZC, Carroll A, et al
    Natural history of oral HPV infection - longitudinal analyses in prospective cohorts from Australia.
    Int J Cancer. 2020 Dec 15. doi: 10.1002/ijc.33442.
    PubMed     Abstract available


    November 2020
  48. MALAGON T, Volesky KD, Bouten S, Laprise C, et al
    Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis.
    Int J Cancer. 2020;147:2695-2707.
    PubMed     Abstract available


  49. BIZZARRI N, Anchora LP, Cattani P, De Vincenzo R, et al
    Peritoneal Hpv-Dna Test In Cervical Cancer (Pioneer Study): A Proof Of Concept.
    Int J Cancer. 2020 Nov 5. doi: 10.1002/ijc.33380.
    PubMed     Abstract available


    October 2020
  50. REINHOLDT K, Thomsen LT, Munk C, Dehlendorff C, et al
    Incidence of HPV-related anogenital precancer and cancer in women with diabetes - a nationwide registry-based cohort study.
    Int J Cancer. 2020 Oct 31. doi: 10.1002/ijc.33365.
    PubMed     Abstract available


  51. REZHAKE R, Chen F, Hu SY, Zhao XL, et al
    Triage options to manage high-risk human papillomavirus-positive women: A population-based cross-sectional study from rural China.
    Int J Cancer. 2020;147:2053-2064.
    PubMed     Abstract available


  52. RAMIREZ AT, Sanchez GI, Nedjai B, Agudelo MC, et al
    Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country.
    Int J Cancer. 2020 Oct 2. doi: 10.1002/ijc.33314.
    PubMed     Abstract available


    September 2020
  53. BONDE J, Floore A, Ejegod D, Vink FJ, et al
    Methylation markers FAM19A4 and miR124-2 as triage strategy for primary HPV screen positive women; A large European multi-center study.
    Int J Cancer. 2020 Sep 30. doi: 10.1002/ijc.33320.
    PubMed     Abstract available


  54. PLATH M, Gass J, Hlevnjak M, Li Q, et al
    Unraveling most abundant mutational signatures in head and neck cancer.
    Int J Cancer. 2020 Sep 15. doi: 10.1002/ijc.33297.
    PubMed     Abstract available


  55. TANAKA H, Takemoto N, Horie M, Takai E, et al
    Circulating Tumor HPV DNA Complements PET-CT in Guiding Management after Radiotherapy in HPV-Related Squamous Cell Carcinoma of the Head and Neck.
    Int J Cancer. 2020 Sep 7. doi: 10.1002/ijc.33287.
    PubMed     Abstract available


    July 2020
  56. BURGER EA, Portnoy A, Campos NG, Sy S, et al
    Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
    Int J Cancer. 2020 Jul 24. doi: 10.1002/ijc.33233.
    PubMed     Abstract available


  57. ARBYN M, Gultekin M, Morice P, Nieminen P, et al
    The European response to the WHO call to eliminate cervical cancer as a public health problem.
    Int J Cancer. 2020 Jul 7. doi: 10.1002/ijc.33189.
    PubMed     Abstract available


    June 2020
  58. TOTA JE, Isidean SD, Franco EL
    Defining benchmarks for tolerable risk thresholds in cancer screening: Impact of HPV vaccination on the future of cervical cancer screening.
    Int J Cancer. 2020 Jun 25. doi: 10.1002/ijc.33178.
    PubMed     Abstract available


  59. RAMACHANDRAN D, Schurmann P, Mao Q, Wang Y, et al
    Association of genomic variants at the Human Leukocyte Antigen locus with cervical cancer risk, HPV status, and gene expression.
    Int J Cancer. 2020 Jun 24. doi: 10.1002/ijc.33171.
    PubMed     Abstract available


  60. GRAY P, Kann H, Pimenoff VN, Adhikari I, et al
    Long-term follow-up of human papillomavirus (HPV) type replacement among young pregnant Finnish females before and after a community-randomised HPV vaccination trial with moderate coverage.
    Int J Cancer. 2020 Jun 23. doi: 10.1002/ijc.33169.
    PubMed     Abstract available


  61. LYNGE E, Thamsborg L, Larsen LG, Christensen J, et al
    Prevalence of high-risk human papillomavirus after HPV-vaccination in Denmark.
    Int J Cancer. 2020 Jun 16. doi: 10.1002/ijc.33157.
    PubMed     Abstract available


  62. GALATI L, Combes JD, Gupta P, Sen R, et al
    Detection of a large spectrum of viral infections in conjunctival pre-malignant and malignant lesions.
    Int J Cancer. 2020 Jun 11. doi: 10.1002/ijc.33149.
    PubMed     Abstract available


  63. FARNSWORTH A, Roberts JM, Garland SM, Crescini J, et al
    Detection of high-grade cervical disease among women referred directly to colposcopy following a positive HPV screening test varies with age and cytology findings.
    Int J Cancer. 2020 Jun 2. doi: 10.1002/ijc.33128.
    PubMed     Abstract available


  64. FACOMPRE ND, Rajagopalan P, Sahu V, Pearson AT, et al
    Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models.
    Int J Cancer. 2020 Jun 1. doi: 10.1002/ijc.33125.
    PubMed     Abstract available


    May 2020
  65. JENKINS D, Molijn A, Kazem S, Pirog EC, et al
    Molecular and pathological basis of HPV-negative cervical adenocarcinoma seen in a global study.
    Int J Cancer. 2020 May 31. doi: 10.1002/ijc.33124.
    PubMed     Abstract available


  66. MESSERSCHMIDT C, Obermayer B, Klinghammer K, Ochsenreither S, et al
    Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC.
    Int J Cancer. 2020 May 29. doi: 10.1002/ijc.33123.
    PubMed     Abstract available


  67. LI X, Ding L, Song L, Gao W, et al
    Effects of exposure to polycyclic aromatic hydrocarbons combined with high-risk human papillomavirus infection on cervical intraepithelial neoplasia: A population study in Shanxi Province, China.
    Int J Cancer. 2020;146:2406-2412.
    PubMed     Abstract available


    April 2020
  68. REN J, Xu W, Su J, Ren X, et al
    Multiple imputation and clinico-serological models to predict human papillomavirus status in oropharyngeal carcinoma: An alternative when tissue is unavailable.
    Int J Cancer. 2020;146:2166-2174.
    PubMed     Abstract available


  69. IDAHL A, Cornet CL, Maldonado SG, Waterboer T, et al
    Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort.
    Int J Cancer. 2020 Apr 3. doi: 10.1002/ijc.32999.
    PubMed     Abstract available


    March 2020
  70. HAMMER A, Demarco M, Campos N, Befano B, et al
    Study of the Risks of CIN3+ detection following multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California.
    Int J Cancer. 2020 Mar 6. doi: 10.1002/ijc.32950.
    PubMed     Abstract available


    February 2020
  71. VENETIANER R, Clarke MA, van der Marel J, Tota J, et al
    Identification of HPV Genotypes Causing Cervical Pre-Cancer using Tissue-Based Genotyping.
    Int J Cancer. 2020 Feb 9. doi: 10.1002/ijc.32919.
    PubMed     Abstract available


  72. CLEVELAND AA, Gargano JW, Park IU, Griffin MR, et al
    Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
    Int J Cancer. 2020;146:810-818.
    PubMed     Abstract available


    January 2020
  73. NAKAGAWA T, Matsusaka K, Misawa K, Ota S, et al
    Stratification of HPV-associated and HPV-negative oropharyngeal squamous cell carcinomas based on DNA methylation epigenotypes.
    Int J Cancer. 2020 Jan 30. doi: 10.1002/ijc.32890.
    PubMed     Abstract available


  74. ZHAO XL, Xu XQ, Duan XZ, Rezhake R, et al
    Comparative performance evaluation of different HPV tests and triaging strategies using self-samples and feasibility assessment of thermal ablation in 'colposcopy and treat' approach: a population-based study in rural China.
    Int J Cancer. 2020 Jan 22. doi: 10.1002/ijc.32881.
    PubMed     Abstract available


  75. CHAN K, Liu SS, Wei N, Ngu SF, et al
    Primary HPV testing with cytology versus cytology alone in cervical screening - a prospective randomized controlled trial (RCT) with two rounds of screening in a Chinese population.
    Int J Cancer. 2020 Jan 10. doi: 10.1002/ijc.32861.
    PubMed     Abstract available


    December 2019
  76. GABY S, Eva E, Andreas W, Wilhelm O, et al
    Reducing Overtreatment Associated with Overdiagnosis in Cervical Cancer Screening - A Model-based Benefit-Harm Analysis for Austria.
    Int J Cancer. 2019 Dec 24. doi: 10.1002/ijc.32849.
    PubMed     Abstract available


  77. KANN H, Hortlund M, Eklund C, Dillner J, et al
    Human Papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
    Int J Cancer. 2019 Dec 23. doi: 10.1002/ijc.32848.
    PubMed     Abstract available


  78. ELFSTROM KM, Sundstrom K, Andersson S, Bzhalava Z, et al
    Increasing participation in cervical screening by targeting long-term nonattenders: Randomized health services study.
    Int J Cancer. 2019;145:3033-3039.
    PubMed     Abstract available


    November 2019
  79. VEYER D, Wack M, Mandavit M, Garrigou S, et al
    HPV circulating tumoral DNA quantification by droplet-based digital PCR: a promising predictive and prognostic biomarker for HPV-associated oropharyngeal cancers.
    Int J Cancer. 2019 Nov 22. doi: 10.1002/ijc.32804.
    PubMed    


  80. LEHTINEN M, Apter D, Eriksson T, Harjula K, et al
    Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females - results from a community-randomized trial.
    Int J Cancer. 2019 Nov 17. doi: 10.1002/ijc.32791.
    PubMed     Abstract available


  81. COSPER PF, McNair C, Gonzalez I, Wong N, et al
    Decreased Local Immune Response and Retained HPV Gene Expression during Chemoradiotherapy are Associated with Treatment Resistance and Death from Cervical Cancer.
    Int J Cancer. 2019 Nov 15. doi: 10.1002/ijc.32793.
    PubMed     Abstract available


  82. YANG Y, Meng YL, Duan SM, Zhan SB, et al
    REBACIN(R) as a noninvasive clinical intervention for high-risk human papillomavirus persistent infection.
    Int J Cancer. 2019;145:2712-2719.
    PubMed     Abstract available


  83. ORUMAA M, Leinonen MK, Campbell S, Moller B, et al
    Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016.
    Int J Cancer. 2019;145:2629-2638.
    PubMed     Abstract available


  84. COMBES JD, Clifford GM, Gunthard HF, Hauser C, et al
    Antibodies against HPV16E6 oncoprotein in the Swiss HIV Cohort Study: kinetics and anal cancer risk prediction.
    Int J Cancer. 2019 Nov 12. doi: 10.1002/ijc.32784.
    PubMed     Abstract available


    October 2019
  85. SAND FL, Kjaer SK, Frederiksen K, Dehlendorff C, et al
    Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status.
    Int J Cancer. 2019 Oct 24. doi: 10.1002/ijc.32752.
    PubMed     Abstract available


  86. FOKOM DOMGUE J, Futuh B, Ngalla C, Kakute P, et al
    Feasibility of a Community-based Cervical Cancer Screening with 'Test and Treat' strategy using self-sample for an HPV Test: Experience from rural Cameroon, Africa.
    Int J Cancer. 2019 Oct 21. doi: 10.1002/ijc.32746.
    PubMed     Abstract available


  87. BRAUN JA, Herrmann AL, Blase JI, Frensemeier K, et al
    Effects of the Antifungal Agent Ciclopirox in HPV-Positive Cancer Cells: Repression of Viral E6/E7 Oncogene Expression and Induction of Senescence and Apoptosis.
    Int J Cancer. 2019 Oct 11. doi: 10.1002/ijc.32709.
    PubMed     Abstract available


  88. MADATHIL S, Rousseau MC, Joseph L, Coutlee F, et al
    Latency of tobacco smoking for head and neck cancer among HPV-positive and HPV-negative individuals.
    Int J Cancer. 2019 Oct 4. doi: 10.1002/ijc.32708.
    PubMed     Abstract available


  89. ZORZI M, Del Mistro A, Giorgi Rossi P, Laurino L, et al
    Risk of CIN2 or more severe lesions after negative HPV-mRNA E6/E7 overexpression assay and after negative HPV-DNA test: concurrent cohorts with a 5-year follow up.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32695.
    PubMed     Abstract available


  90. BETTAMPADI D, Villa LL, Lazcano Ponce E, Salmeron J, et al
    Oral Human Papillomavirus Prevalence and Type Distribution by Country (Brazil, Mexico and the United States) and Age among HPV Infection in Men (HIM) Study Participants.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32713.
    PubMed     Abstract available


  91. CASTLE PE, Burk RD, Massad LS, Eltoum IE, et al
    Epidemiological Evidence that Common HPV Types May Be Common Because of Their Ability to Evade Immune Surveillance: Results from the Women's Interagency HIV Study.
    Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32693.
    PubMed     Abstract available


    September 2019
  92. SADRI NAHAND J, Moghoofei M, Salmaninejad A, Bahmanpour Z, et al
    Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review.
    Int J Cancer. 2019 Sep 30. doi: 10.1002/ijc.32688.
    PubMed     Abstract available


  93. KANO M, Kondo S, Wakisaka N, Wakae K, et al
    Expression of estrogen receptor alpha is associated with pathogenesis and prognosis of human papillomavirus-positive oropharyngeal cancer.
    Int J Cancer. 2019;145:1547-1557.
    PubMed     Abstract available


  94. REN J, Yang W, Su J, Ren X, et al
    Human papillomavirus and p16 immunostaining, prevalence and prognosis of squamous carcinoma of unknown primary in the head and neck region.
    Int J Cancer. 2019;145:1465-1474.
    PubMed     Abstract available


    August 2019
  95. SILLING S, Soylemez U, Mauch C, Zigrino P, et al
    Human papillomavirus type 197 is not associated with skin tumors.
    Int J Cancer. 2019 Aug 28. doi: 10.1002/ijc.32646.
    PubMed    


  96. ARROYO MUHR LS, Dillner J
    Reply to: Human papillomavirus type 197 is not associated with skin tumors.
    Int J Cancer. 2019 Aug 28. doi: 10.1002/ijc.32645.
    PubMed    


  97. GANGKOFNER DS, Holzinger D, Schroeder L, Eichmuller SB, et al
    Patterns of antibody responses to non-viral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status.
    Int J Cancer. 2019 Aug 12. doi: 10.1002/ijc.32623.
    PubMed     Abstract available


  98. VINK FJ, Meijer CJLM, Clifford GM, Poljak M, et al
    FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study.
    Int J Cancer. 2019 Aug 7. doi: 10.1002/ijc.32614.
    PubMed     Abstract available


  99. WEI F, Su Y, Yao X, Cui X, et al
    Sex differences in the incidence and clearance of anal human papillomavirus infection among heterosexual men and women in Liuzhou, China: An observational cohort study.
    Int J Cancer. 2019;145:807-816.
    PubMed     Abstract available


  100. AKGUL B, Kirschberg M, Storey A, Hufbauer M, et al
    Human papillomavirus type 8 oncoproteins E6 and E7 cooperate in downregulation of the cellular checkpoint kinase-1.
    Int J Cancer. 2019;145:797-806.
    PubMed     Abstract available


  101. GANLY I, Yang L, Giese RA, Hao Y, et al
    Periodontal pathogens are a risk factor of oral cavity squamous cell carcinoma, independent of tobacco and alcohol and human papillomavirus.
    Int J Cancer. 2019;145:775-784.
    PubMed     Abstract available


  102. RIGHOLT CH, Bozat-Emre S, Mahmud SM
    Effectiveness of school-based and high-risk human papillomavirus vaccination programs against cervical dysplasia in Manitoba, Canada.
    Int J Cancer. 2019;145:671-677.
    PubMed     Abstract available


    July 2019
  103. DOVEY DE LA COUR C, Dehlendorff C, Aalborg GL, von Buchwald C, et al
    Use of nonaspirin non-steroidal anti-inflammatory drugs and risk of head and neck cancer: a nationwide case-control study.
    Int J Cancer. 2019 Jul 2. doi: 10.1002/ijc.32544.
    PubMed     Abstract available


  104. BERTOLI HK, Rasmussen CL, Sand FL, Albieri V, et al
    Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina.
    Int J Cancer. 2019;145:78-86.
    PubMed     Abstract available


    June 2019
  105. PARKIN DM, Hammerl L, Ferlay J, Kantelhardt EJ, et al
    Cancer in Africa 2018: the role of infections.
    Int J Cancer. 2019 Jun 29. doi: 10.1002/ijc.32538.
    PubMed     Abstract available


    April 2019
  106. AMARO-FILHO SM, Gradissimo A, Usyk M, Moreira FCB, et al
    HPV73 a non-vaccine type causes cervical cancer.
    Int J Cancer. 2019 Apr 9. doi: 10.1002/ijc.32315.
    PubMed     Abstract available


    December 2018
  107. ANDREASSEN T, Hansen BT, Engesaeter B, Hashim D, et al
    Psychological Effect of Cervical Cancer Screening When Changing Primary Screening Method From Cytology to hrHPV testing.
    Int J Cancer. 2018 Dec 14. doi: 10.1002/ijc.32067.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Sexually Transmitted Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: